$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

$rmti Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024012572 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$22.68M	$22.09M	$83.61M
YoY Change	15.29%	14.39%	14.84%
Cost Of Revenue	$19.61M	$19.22M	$74.91M
YoY Change	14.9%	13.26%	8.98%
Gross Profit	$3.064M	$2.870M	$8.704M
YoY Change	17.89%	22.65%	113.49%
Gross Profit Margin	13.51%	12.99%	10.41%
Selling, General & Admin	$4.370M	$3.249M	$14.27M
YoY Change	16.6%	-21.71%	-19.57%
% of Gross Profit	142.62%	113.21%	163.91%
Research & Development	$18.00K	$168.0K	$1.100M
YoY Change	-93.53%	7.69%	-64.52%
% of Gross Profit	0.59%	5.85%	12.64%
Depreciation & Amortization	$545.0K	$550.0K	$1.444M
YoY Change	240.63%	252.56%	150.69%
% of Gross Profit	17.79%	19.16%	16.59%
Operating Expenses	$4.388M	$3.417M	$15.37M
YoY Change	8.99%	-20.65%	-26.25%
Operating Profit	-$1.324M	-$547.0K	-$6.670M
YoY Change	-7.22%	-72.18%	-60.25%
Interest Expense	$431.0K	-$965.0K	$2.301M
YoY Change	11.37%	144.92%	18.85%
% of Operating Profit
Other Income/Expense, Net	-$407.0K		-$1.769M
YoY Change	26.01%		-6.85%
Pretax Income	-$1.731M	-$1.512M	-$8.439M
YoY Change	-1.09%	-35.93%	-54.82%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.731M	-$1.512M	-$8.439M
YoY Change	-1.09%	-35.93%	-54.82%
Net Earnings / Revenue	-7.63%	-6.84%	-10.09%
Basic Earnings Per Share	-$0.06		-$0.37
Diluted Earnings Per Share	-$0.06	-$0.05	-$0.37
COMMON SHARES
Basic Shares Outstanding	29.33M shares	28.49M shares	23.32M shares
Diluted Shares Outstanding	29.33M shares		23.32M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.619M	$10.94M	$10.94M
YoY Change	-48.8%	-49.12%	-49.12%
Cash & Equivalents	$6.642M	$8.983M	$8.983M
Short-Term Investments	$1.977M	$1.952M	$1.952M
Other Short-Term Assets	$910.0K	$1.063M	$1.063M
YoY Change	-26.61%	-39.08%	-39.08%
Inventory	$6.073M	$5.871M	$5.871M
Prepaid Expenses
Receivables	$11.09M	$10.90M	$10.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$26.70M	$28.77M	$28.77M
YoY Change	-10.08%	-18.52%	-18.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.134M	$6.402M	$11.02M
YoY Change	181.51%	191.8%	28.04%
Goodwill	$921.0K	$900.0K
YoY Change	0.0%	0.0%
Intangibles	$10.62M	$10.76M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$527.0K	$527.0K	$705.0K
YoY Change	0.96%	0.76%	-60.81%
Total Long-Term Assets	$24.03M	$23.40M	$23.40M
YoY Change	122.84%	106.65%	106.65%
TOTAL ASSETS
Total Short-Term Assets	$26.70M	$28.77M	$28.77M
Total Long-Term Assets	$24.03M	$23.40M	$23.40M
Total Assets	$50.72M	$52.17M	$52.17M
YoY Change	25.33%	11.88%	11.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.919M	$4.516M	$4.516M
YoY Change	-5.44%	11.42%	11.42%
Accrued Expenses	$5.253M	$7.149M	$8.530M
YoY Change	20.51%	-7.18%	-12.13%
Deferred Revenue	$46.00K	$46.00K
YoY Change	-82.24%	-97.34%
Short-Term Debt	$0.00	$244.0K	$244.0K
YoY Change		-51.49%	-51.49%
Long-Term Debt Due	$566.0K	$0.00	$558.0K
YoY Change	-81.92%	-100.0%	-65.79%
Total Short-Term Liabilities	$14.95M	$16.64M	$16.64M
YoY Change	-0.8%	-5.96%	-5.96%
LONG-TERM LIABILITIES
Long-Term Debt	$8.265M	$8.293M	$9.823M
YoY Change	34.46%	9.77%	30.02%
Other Long-Term Liabilities	$14.00K	$14.00K	$4.422M
YoY Change	0.0%	0.0%	-39.28%
Total Long-Term Liabilities	$8.279M	$8.307M	$14.25M
YoY Change	34.38%	9.75%	-4.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.95M	$16.64M	$16.64M
Total Long-Term Liabilities	$8.279M	$8.307M	$14.25M
Total Liabilities	$30.08M	$30.88M	$30.88M
YoY Change	7.7%	-5.06%	-5.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$398.9M	-$397.2M
YoY Change	2.16%	2.16%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.64M	$21.30M	$21.29M
YoY Change
Total Liabilities & Shareholders Equity	$50.72M	$52.17M	$52.17M
YoY Change	25.33%	11.88%	11.88%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.731M	-$1.512M	-$8.439M
YoY Change	-1.09%	-35.93%	-54.82%
Depreciation, Depletion And Amortization	$545.0K	$550.0K	$1.444M
YoY Change	240.63%	252.56%	150.69%
Cash From Operating Activities	-$2.400M	-$43.00K	-$9.400M
YoY Change	-38.46%	-92.76%	-45.98%
INVESTING ACTIVITIES
Capital Expenditures	$139.0K	$43.00K	$12.65M
YoY Change	-367.31%	-46.91%	4400.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.051M	$9.600M
YoY Change	-100.0%	-37.94%	-553.9%
Cash From Investing Activities	-$139.0K	$2.008M	-$3.045M
YoY Change	-102.62%	-37.52%	27.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.86M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$178.0K	-742.0K	$11.34M
YoY Change	-128.21%	-86.5%	-31.81%
NET CHANGE
Cash From Operating Activities	-$2.400M	-43.00K	-$9.400M
Cash From Investing Activities	-$139.0K	2.008M	-$3.045M
Cash From Financing Activities	$178.0K	-742.0K	$11.34M
Net Change In Cash	-$2.341M	1.223M	-$1.119M
YoY Change	-395.58%	-142.49%	-64.79%
FREE CASH FLOW
Cash From Operating Activities	-$2.400M	-$43.00K	-$9.400M
Capital Expenditures	$139.0K	$43.00K	$12.65M
Free Cash Flow	-$2.539M	-$86.00K	-$22.05M
YoY Change	-34.02%	-87.26%	24.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3317208
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	30142 S. Wixom Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Wixom
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48393
CY2023	dei	City Area Code CityAreaCode	248
CY2023	dei	Local Phone Number LocalPhoneNumber	960‑9009
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $.0001
CY2023	dei	Trading Symbol TradingSymbol	RMTI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023Q4	us-gaap	Notes Payable NotesPayable	244000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	503000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8439000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1936000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	114000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23322915	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001041024
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.091
CY2023Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://rockwellmed.com/20231231#FinanceAndOperatingLeaseLiabilityCurrent http://rockwellmed.com/20231231#FinanceAndOperatingLeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://rockwellmed.com/20231231#FinanceAndOperatingLeaseLiabilityCurrent http://rockwellmed.com/20231231#FinanceAndOperatingLeaseLiabilityNoncurrent
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-23661
CY2023	dei	Entity Registrant Name EntityRegistrantName	ROCKWELL MEDICAL, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	91048814	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29334617	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	274
CY2023	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2023	dei	Auditor Location AuditorLocation	West Palm Beach, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8983000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10102000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1952000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11390000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	81000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	33000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10901000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6259000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5871000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5814000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1063000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1745000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	28770000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	35310000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6402000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2194000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	178000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1276000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2713000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3943000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1903000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2468000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10759000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	921000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	921000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	527000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	523000	usd
CY2023Q4	us-gaap	Assets Assets	52173000	usd
CY2022Q4	us-gaap	Assets Assets	46635000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4516000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4053000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7149000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7702000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2500000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1381000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1483000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	558000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	522000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	46000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1731000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1631000	usd
CY2023Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	243000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	66000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16637000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17691000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1433000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2581000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1530000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2088000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8293000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7555000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	475000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2600000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2500000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	30882000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	32529000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29130607	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29130607	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12163673	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12163673	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	3000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418487000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402701000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-397198000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388759000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	163000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21291000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14106000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52173000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46635000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	83612000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	72810000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	74908000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	68733000	usd
CY2023	us-gaap	Gross Profit GrossProfit	8704000	usd
CY2022	us-gaap	Gross Profit GrossProfit	4077000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1107000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3119000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2125000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2094000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12142000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15644000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6670000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-16780000	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	321000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2301000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	211000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	33000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18679000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23322915	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23322915	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14304512	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14304512	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8439000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18679000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-159000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	114000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8603000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18568000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2535000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14916000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	315000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	932000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21291000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8439000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18679000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1444000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	576000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	932000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	315000	usd
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	1098000	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	610000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2010000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2013000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1107000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	369000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3000	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	321000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4642000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	346000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1176000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2101000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1410000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2720000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	463000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	314000	usd
CY2023	rmti	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	1465000	usd
CY2022	rmti	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	1421000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-376000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2534000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3810000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3826000	usd
CY2023	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	7244000	usd
CY2022	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	2126000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9412000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16929000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5701000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	21297000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	15301000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	19182000	usd
CY2023	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	284000	usd
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	281000	usd
CY2023	rmti	Payments To Acquire Machinery And Equipment Excluding Cash Paid In Asset Acquisition PaymentsToAcquireMachineryAndEquipmentExcludingCashPaidInAssetAcquisition	12361000	usd
CY2022	rmti	Payments To Acquire Machinery And Equipment Excluding Cash Paid In Asset Acquisition PaymentsToAcquireMachineryAndEquipmentExcludingCashPaidInAssetAcquisition	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3045000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2396000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	2000000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	11750000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	992000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1443000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	522000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	482000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14861000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15016000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	106000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	15000000	usd
CY2023	rmti	Payments Of Stock Issuance Costs Preferred Stock PaymentsOfStockIssuanceCostsPreferredStock	0	usd
CY2022	rmti	Payments Of Stock Issuance Costs Preferred Stock PaymentsOfStockIssuanceCostsPreferredStock	85000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11342000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16150000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1119000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3178000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10102000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13280000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8983000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10102000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1209000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1470000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-159000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	114000	usd
CY2023	us-gaap	Notes Assumed1 NotesAssumed1	733000	usd
CY2022	us-gaap	Notes Assumed1 NotesAssumed1	503000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	501000	usd
CY2023	rmti	Asset Acquisition Deferred Consideration AssetAcquisitionDeferredConsideration	5000000	usd
CY2022	rmti	Asset Acquisition Deferred Consideration AssetAcquisitionDeferredConsideration	0	usd
CY2023	rmti	Area Of Operating Space AreaOfOperatingSpace	175000	sqft
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-397200000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21300000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	10900000	usd
CY2023Q4	rmti	Working Capital Net WorkingCapitalNet	12100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9400000	usd
CY2023Q4	rmti	Sale Of Stock Aggregate Consideration Authorized Remaining Amount SaleOfStockAggregateConsiderationAuthorizedRemainingAmount	11000000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation, including the reclassification of lease right-of-use assets into Right of Use Assets - Operating, Net and Right of Use Assets - Financing, Net and lease liabilities into Lease Liabilities - Operating, Current, Lease Liabilities - Financing, Current, Lease Liabilities - Operating, Long-Term, and Lease Liabilities - Financing, Long-Term. Additionally, amounts from the Changes in Lease Liabilities were reclassified to Payments on Financing Lease Liabilities on the statement of cash flows.</span></div>
CY2023	rmti	Average Payment Term Of Customers AveragePaymentTermOfCustomers	P30D
CY2023	rmti	Average Payment Term Of Distributors AveragePaymentTermOfDistributors	P60D
CY2023	rmti	Number Of Distribution And License Agreements NumberOfDistributionAndLicenseAgreements	5	agreement
CY2023	rmti	Product Purchase Agreement Purchase Forecasts Period ProductPurchaseAgreementPurchaseForecastsPeriod	P9M
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	83612000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	72810000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	10901000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	6259000	usd
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	5913000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	521000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4331000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8157000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3800000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3800000	usd
CY2023Q4	rmti	Revenue Remaining Performance Obligation Amount RevenueRemainingPerformanceObligationAmount	500000	usd
CY2022Q4	rmti	Revenue Remaining Performance Obligation Amount RevenueRemainingPerformanceObligationAmount	2900000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the financial statements include estimates associated with fair value and classification of warrants, revenue recognition, allowance for credit losses, inventory reserves, accrued expenses, deferred license revenue, stock-based compensation, valuations and impairments of long-lived assets, and accounting for income taxes.</span></div>
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1100000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3100000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14304512	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14304512	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6745421	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12892700	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8439000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18679000	usd
CY2023	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	150000	usd
CY2022	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8589000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8589000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18679000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18679000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23322915	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14304512	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14304512	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	1948000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1952000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	11315000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	75000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11390000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2250000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3351000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	351000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	351000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3270000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2112000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5871000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5814000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	178000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1276000	usd
CY2023Q4	rmti	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	6049000	usd
CY2022Q4	rmti	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	7090000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15206000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9830000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8804000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7636000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6402000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2194000	usd
CY2023	us-gaap	Depreciation Depreciation	1200000	usd
CY2022	us-gaap	Depreciation Depreciation	600000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2413000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2568000	usd
CY2023Q4	rmti	Accrued Unvouchered Receipts Current AccruedUnvoucheredReceiptsCurrent	1663000	usd
CY2022Q4	rmti	Accrued Unvouchered Receipts Current AccruedUnvoucheredReceiptsCurrent	585000	usd
CY2023Q4	rmti	Accrued Manufacturing Expense Current AccruedManufacturingExpenseCurrent	1064000	usd
CY2022Q4	rmti	Accrued Manufacturing Expense Current AccruedManufacturingExpenseCurrent	0	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	254000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	306000	usd
CY2023Q4	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	0	usd
CY2022Q4	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	43000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1755000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4200000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7149000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7702000	usd
CY2023	rmti	Deferred License Revenue Revenue Recognized During Period DeferredLicenseRevenueRevenueRecognizedDuringPeriod	1500000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29130607	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29130607	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12163673	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12163673	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29130607	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12163673	shares
CY2023Q4	rmti	Common Stock And Pre Funded Warrants Shares Outstanding CommonStockAndPreFundedWarrantsSharesOutstanding	29130607	shares
CY2022Q4	rmti	Common Stock And Pre Funded Warrants Shares Outstanding CommonStockAndPreFundedWarrantsSharesOutstanding	18463673	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3793388	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10196268	shares
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	1363636	shares
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	1363636	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1328621	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1206905	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	35876028	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	31356373	shares
CY2022Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	12900000	usd
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	932000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	315000	usd
CY2018Q4	rmti	Number Of Additional Agreements NumberOfAdditionalAgreements	3	agreement
CY2023Q4	rmti	Self Insurance Reserve Per Occurrence SelfInsuranceReservePerOccurrence	350000	usd
CY2023	rmti	Self Insurance Overall Limit SelfInsuranceOverallLimit	618000	usd
CY2023Q4	rmti	Self Insurance Retention Limits In Excess Of Claims Paid And Accrued SelfInsuranceRetentionLimitsInExcessOfClaimsPaidAndAccrued	535000	usd
CY2023Q4	rmti	Self Insurance Estimated Loss Reserves And Additional Future Claims SelfInsuranceEstimatedLossReservesAndAdditionalFutureClaims	254000	usd
CY2023Q4	rmti	Cash Collateral And Escrow Deposit Held By Insurance Carriers For Workers Compensation Insurance CashCollateralAndEscrowDepositHeldByInsuranceCarriersForWorkersCompensationInsurance	400000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1672000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1710000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	497000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	388000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2169000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2098000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	565000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	565000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	147000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	179000	usd
CY2023	rmti	Finance Lease Expense FinanceLeaseExpense	712000	usd
CY2022	rmti	Finance Lease Expense FinanceLeaseExpense	744000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2898000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2859000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1777000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1772000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	147000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	179000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	522000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	482000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	768000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1511000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	672000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1021000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	676000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	362000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	666000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	129000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	311000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3025000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2325000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	211000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	237000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2814000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2088000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1772000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4361000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	0	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1772000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4361000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	72612000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70686000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7856000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7792000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	6872000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	6872000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	459000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	371000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	398000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	234000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	144000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	605000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	118000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	983000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1989000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1274000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	90448000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	88817000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	259000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	224000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	181000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	316000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	35000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	475000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	548000	usd
CY2023Q4	rmti	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	89973000	usd
CY2022Q4	rmti	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	88269000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	89973000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	88269000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	321400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	164700000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd

Files In Submission

Name	View Source	Status
0001628280-24-012572-index-headers.html	Edgar Link	pending
0001628280-24-012572-index.html	Edgar Link	pending
0001628280-24-012572.txt	Edgar Link	pending
0001628280-24-012572-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rmti-20231231.htm	Edgar Link	pending
rmti-20231231.xsd	Edgar Link	pending
rmti-20231231x10kxex1030.htm	Edgar Link	pending
rmti-20231231x10kxex1032.htm	Edgar Link	pending
rmti-20231231x10kxex231.htm	Edgar Link	pending
rmti-20231231x10kxex232.htm	Edgar Link	pending
rmti-20231231x10kxex311.htm	Edgar Link	pending
rmti-20231231x10kxex321.htm	Edgar Link	pending
rmti-20231231_def.xml	Edgar Link	unprocessable
rmti-20231231_lab.xml	Edgar Link	unprocessable
rmti-20231231_htm.xml	Edgar Link	completed
rmti-2023x12x31x10kxex1031.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rmti-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
rmti-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

2024 Q1 Form 10-K Financial Statement

#000162828024012572 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI ROCKWELL MEDICAL, INC. Stock $rmti

2024 Q1 Form 10-K Financial Statement

#000162828024012572 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti